MA33537B1 - Anticorps anti-cdcp1 humanisés - Google Patents

Anticorps anti-cdcp1 humanisés

Info

Publication number
MA33537B1
MA33537B1 MA34651A MA34651A MA33537B1 MA 33537 B1 MA33537 B1 MA 33537B1 MA 34651 A MA34651 A MA 34651A MA 34651 A MA34651 A MA 34651A MA 33537 B1 MA33537 B1 MA 33537B1
Authority
MA
Morocco
Prior art keywords
against human
antibodies against
antibodies
cdcp1
human cdcp1
Prior art date
Application number
MA34651A
Other languages
Arabic (ar)
English (en)
Inventor
Johannes Auer
Birgit Bossenmaier
Guy Georges
Alexander Lifke
Ekkehard Moessner
Gerhard Niederfellner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MA33537B1 publication Critical patent/MA33537B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps humanisés contre le cdcp1 humain (anticorps anti-cdcp1), des procédés de production desdits anticorps, des compositions pharmaceutiques contenant lesdits anticorps, et des utilisations de ceux-ci.
MA34651A 2009-08-28 2012-02-27 Anticorps anti-cdcp1 humanisés MA33537B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09011046 2009-08-28
EP10000972 2010-02-01
PCT/EP2010/005244 WO2011023389A1 (fr) 2009-08-28 2010-08-26 Anticorps anti-cdcp1 humanisés

Publications (1)

Publication Number Publication Date
MA33537B1 true MA33537B1 (fr) 2012-08-01

Family

ID=43086176

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34651A MA33537B1 (fr) 2009-08-28 2012-02-27 Anticorps anti-cdcp1 humanisés

Country Status (23)

Country Link
US (2) US8394928B2 (fr)
EP (1) EP2470567A1 (fr)
JP (1) JP5647687B2 (fr)
KR (1) KR101495407B1 (fr)
CN (1) CN102482357B (fr)
AR (1) AR077973A1 (fr)
AU (1) AU2010288879A1 (fr)
BR (1) BR112012004221A2 (fr)
CA (1) CA2770161A1 (fr)
CL (1) CL2012000524A1 (fr)
CO (1) CO6511201A2 (fr)
CR (1) CR20120038A (fr)
EC (1) ECSP12011701A (fr)
IL (1) IL217919A0 (fr)
MA (1) MA33537B1 (fr)
MX (1) MX2012002458A (fr)
NZ (1) NZ597664A (fr)
PE (1) PE20121063A1 (fr)
RU (1) RU2571207C2 (fr)
SG (1) SG178886A1 (fr)
TW (1) TWI412375B (fr)
UA (1) UA106890C2 (fr)
WO (1) WO2011023389A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) * 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
AR092044A1 (es) 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
PT2928923T (pt) 2012-12-10 2020-03-27 Biogen Ma Inc Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
WO2014172448A2 (fr) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Anticorps diriges contre le recepteur d'activine de type ii (actrii)
WO2015082446A1 (fr) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Traitement du cancer à l'aide d'un anticorps anti-cdcp1 et d'un taxane
CN106163560A (zh) 2014-01-24 2016-11-23 亨利·M·杰克逊军事医学促进基金会 针对亨德拉和尼帕病毒的f糖蛋白的抗体
US20170158753A1 (en) * 2014-06-25 2017-06-08 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
US10928391B2 (en) * 2017-06-06 2021-02-23 The Cleveland Clinic Foundation CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
WO2019084319A1 (fr) 2017-10-25 2019-05-02 The Regents Of The University Of California Anticorps contre cdcp1 pour le traitement et la détection du cancer
MX2021005377A (es) 2018-11-09 2021-09-14 Beth Israel Deaconess Medical Ct Inc Terapias dirigidas a cdcp1.
MX2021009119A (es) * 2019-02-01 2022-01-18 Fond Per Listituto Oncologico Di Ricerca Ior Metodos de tratamiento contra el cancer de prostata resistente a la castracion.
CN118440202A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
KR102911451B1 (ko) * 2022-05-24 2026-01-09 건국대학교 글로컬산학협력단 Rps3 결합 단클론 항체 및 이의 용도
CN117264055A (zh) * 2022-06-14 2023-12-22 上海恒润达生生物科技股份有限公司 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
KR20250028265A (ko) * 2022-06-20 2025-02-28 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. 항체 및 이의 용도
CN119836306A (zh) 2022-07-15 2025-04-15 费恩治疗有限公司 与cdcp1结合的抗体药物缀合物和其用途
KR20240057529A (ko) * 2022-10-24 2024-05-03 주식회사 노벨티노빌리티 신규 항-cdcp1 항체 및 이의 용도
WO2025199124A1 (fr) * 2024-03-19 2025-09-25 Tavotek Lab Inc Anticorps ciblant cd318 (cdcp1) et leurs utilisations
WO2025207944A1 (fr) * 2024-03-29 2025-10-02 Sidewinder Therapeutics, Inc. Anticorps se liant au fgfr3-iiib
WO2025262641A1 (fr) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Conjugués anticorps-médicament qui se lient à cdcp1 et leurs utilisations
WO2026078443A1 (fr) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Conjugués anticorps-médicament qui se lient à cdcp1 et leurs utilisations

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0938506B1 (fr) * 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Domaines de la superfamille des immunoglobulines et fragments presentant une solubilite accrue
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1329061A (zh) 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸
WO2002004508A1 (fr) 2000-07-07 2002-01-17 Boehringer Ingelheim International Gmbh Antigene specifique de tumeur (b345) se caracterisant par une sequence d'acides amines telle que dans seq id no 4
NZ581474A (en) * 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE10242146A1 (de) 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
AU2004213568A1 (en) 2003-02-19 2004-09-02 Novartis Ag Glycoprotein antigen SIMA135 expressed in metastatic human tumor cells
EP1648511A1 (fr) 2003-07-29 2006-04-26 Morphotek, Inc. Anticorps et procedes permettant de produire des anticorps genetiquement modifies presentant une fonction effectrice amelioree
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2007024249A2 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
CA2605697A1 (fr) 2005-04-26 2006-11-02 Bioren, Inc. Procede de production d'anticorps igg humains a fonctions effectrices renforcees
WO2007005502A2 (fr) 2005-06-30 2007-01-11 Applera Corporation Procedes et compositions permettant de traiter des maladies en ciblant cdcp1
RU2482132C2 (ru) 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
JP2007112734A (ja) * 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體

Also Published As

Publication number Publication date
US20130209455A1 (en) 2013-08-15
WO2011023389A1 (fr) 2011-03-03
SG178886A1 (en) 2012-04-27
US8394928B2 (en) 2013-03-12
AR077973A1 (es) 2011-10-05
EP2470567A1 (fr) 2012-07-04
HK1167412A1 (en) 2012-11-30
BR112012004221A2 (pt) 2016-11-29
CO6511201A2 (es) 2012-08-31
CN102482357B (zh) 2014-06-11
CL2012000524A1 (es) 2012-08-17
TW201110983A (en) 2011-04-01
NZ597664A (en) 2013-03-28
UA106890C2 (uk) 2014-10-27
US9346886B2 (en) 2016-05-24
CA2770161A1 (fr) 2011-03-03
RU2012111708A (ru) 2013-10-10
AU2010288879A1 (en) 2012-02-02
CN102482357A (zh) 2012-05-30
PE20121063A1 (es) 2012-08-09
ECSP12011701A (es) 2012-03-30
RU2571207C2 (ru) 2015-12-20
KR101495407B1 (ko) 2015-02-24
US20110052582A1 (en) 2011-03-03
MX2012002458A (es) 2012-03-14
TWI412375B (zh) 2013-10-21
JP2013502904A (ja) 2013-01-31
JP5647687B2 (ja) 2015-01-07
CR20120038A (es) 2012-04-18
KR20120089658A (ko) 2012-08-13
IL217919A0 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
MA33892B1 (fr) Anticorps anti-her3, et leurs utilisations
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MA32713B1 (fr) Anticorps anti-egfr/anti-igf-1r bispecifiques
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
MY171841A (en) Antibody formulation
MA34091B1 (fr) Anticorps anti-cd40
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
MA34172B1 (fr) Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
FR2883179B1 (fr) Comprime enrobe
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
CO6571886A2 (es) Antagonistas de pcsk9
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها